- $849.87m
- $760.36m
- $14.08m
Arbutus rises after FDA lifts clinical hold for experimental hepatitis B drug
Brief: Arbutus Announces Final Results Of Its Us$230 Million Modified “Dutch Auction” Tender Offer
Brief: Arbutus Announces Preliminary Results Of Its Us$230 Million Modified “Dutch Auction” Tender Offer
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare
U.S. STOCKS ON THE MOVE-NetEase, Werewolf Therapeutics, JP Morgan
U.S. STOCKS ON THE MOVE-Ubiquiti, BJ's Wholesale, Arbutus
Arbutus climbs after unveiling buyback from Moderna settlement proceeds
Refile: Arbutus Biopharma swings to Q2 loss as revenue falls; plans up to $230 mln shareholder returns
Arbutus Biopharma Corp expected to post a loss of 2 cents a share - Earnings Preview
Arbutus Biopharma Q1 revenue surges on Moderna settlement
U.S. STOCKS ON THE MOVE-Nike, PNC Financia, OSI Systems
U.S. STOCKS ON THE MOVE-Nike, PNC Financial, Papa John's
U.S. STOCKS ON THE MOVE-Gitlab, Snap, Robinhood
Arbutus rises as FDA grants fast-track status to hepatitis B drug
Street View: Wall Street views Moderna's legal settlement as clearing a major overhang
Moderna climbs after $2.25 billion settlement for COVID vaccine patent dispute
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute (updated)
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
Brief: Roivant Announces Genevant Sciences’ And Arbutus Biopharma’S $2.25 Billion Global Settlement With Moderna